Lehtonen A, Marniemi J
Atherosclerosis. 1984 May-Jun;51(2-3):335-8. doi: 10.1016/0021-9150(84)90181-3.
The effect of atenolol on plasma HDL cholesterol subfractions and other plasma lipids in 18 patients with essential hypertension was studied. The atenolol was given orally, in a dose of 100 mg once daily for 6 months. The level of HDL cholesterol during atenolol treatment was significantly lower than before it. The concentration of HDL2 cholesterol decreased (P less than 0.01) during the first month of therapy and remained constant during treatment. The level of HDL3 cholesterol decreased slightly but not significantly. The concentrations of plasma triglycerides and total cholesterol increased slightly during atenolol treatment; statistical significance was reached (P less than 0.05) at 6 months.
研究了阿替洛尔对18例原发性高血压患者血浆高密度脂蛋白胆固醇亚组分及其他血脂的影响。阿替洛尔口服给药,剂量为每日100毫克,持续6个月。阿替洛尔治疗期间高密度脂蛋白胆固醇水平显著低于治疗前。治疗第一个月高密度脂蛋白2胆固醇浓度下降(P<0.01),治疗期间保持稳定。高密度脂蛋白3胆固醇水平略有下降,但无显著差异。阿替洛尔治疗期间血浆甘油三酯和总胆固醇浓度略有升高;6个月时达到统计学显著性(P<0.05)。